Patents by Inventor Fupeng Ma

Fupeng Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7790717
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: September 7, 2010
    Assignee: AstraZeneca AB
    Inventors: Ian Egle, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Heterobicyclic Carboxamides as inhibitors for kinases
    Publication number: 20100168082
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: December 7, 2009
    Publication date: July 1, 2010
    Inventors: Gerald David Artmann, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Piperazine and Piperidine MGLUR5 Potentiators
    Publication number: 20100144710
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof, wherein A, B, D, Ar1, Ar2, R2, R3, R4, a, m and n are defined in the specification, methods for the use thereof, processes for making and pharmaceutical compositions containing the same.
    Type: Application
    Filed: February 28, 2008
    Publication date: June 10, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jalaj Arora, Methvin Isaac, Abdelmalik Slassi, Louise Edwards, Satheesh Nair, Fupeng Ma
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20090275578
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 5, 2009
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20090192169
    Abstract: Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: March 29, 2007
    Publication date: July 30, 2009
    Inventors: Ian Egle, Methvin Isaac, Rebecca Urbanek, Frances M. McLaren, Sally B. Walsh, Gary B. Steelman, Dean G. Brown, David Nugiel, Deborah W. Chen, Abdelmalik Slassi, Fupeng Ma
  • Metabotropic Glutamate Receptor-Potentiating Isoindolones
    Publication number: 20090149505
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, processes for the preparing such compounds, new intermediates employed in their preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventors: James R. Empfield, James J. Folmer, James R. Arnold, Joshua Clayton, Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma
  • SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090124578
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Application
    Filed: January 13, 2009
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Ian EGLE, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090111830
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
    Publication number: 20090069340
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: December 22, 2005
    Publication date: March 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Heather Bunting, Deborah Chen, Ian Egle, Janet Forst, Jennifer Frey, Methvin Isaac, Fupeng Ma, David Nugiel, Abdelmalik Slassi, Gary Steelman, Guang-Ri Sun, Babu Sundar, Radhakrishnan Ukkiramapandian, Rebecca Urbanek, Sally Walsh
  • Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7485722
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: February 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Ian Egle, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20090012089
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: December 6, 2006
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Abdelmalik Slassi, Babu Joseph, Fupeng Ma, Ian Egle, Joshua Clayton, Methvin Isaac, Krzysztof Swierczek
  • Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
    Publication number: 20080318999
    Abstract: The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
    Type: Application
    Filed: July 21, 2006
    Publication date: December 25, 2008
    Inventors: Methvin Isaac, Abdelmalik Slassi, Ian Egle, Fupeng Ma
  • Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842
    Publication number: 20080306077
    Abstract: Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841
    Publication number: 20080306088
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Metabotropic Glutamate-Receptor-Potentiating Isoindolones
    Publication number: 20080227794
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: September 18, 2008
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20080125431
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Application
    Filed: September 12, 2007
    Publication date: May 29, 2008
    Applicant: ASTRAZENECA
    Inventors: Ian Egle, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20070275966
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: December 6, 2006
    Publication date: November 29, 2007
    Applicants: NPS PHARMACEUTICALS, INC., AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma, Babu Joseph, Joshua Clayton, Krzysztof Swierczek
  • Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
    Publication number: 20070032469
    Abstract: The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 8, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS
    Inventors: Methvin Isaac, Abdelmalik Slassi, Ian Egle, Fupeng Ma